ClinicalTrials.gov record
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
ClinicalTrials.gov ID: NCT00996372
Public ClinicalTrials.gov record NCT00996372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
Study identification
- NCT ID
- NCT00996372
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 949 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 35 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2009 (Type not available)
- Primary completion
- Mar 2011 (Actual)
- Completion
- Mar 2011 (Actual)
- Last update posted
- Jun 12, 2014
2009 – 2011
United States locations
- U.S. sites
- 75
- U.S. states
- 31
- U.S. cities
- 65
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 511.130.01074 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 511.130.01046 Boehringer Ingelheim Investigational Site | Huntsville | Alabama | — | — |
| 511.130.01042 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 511.130.01025 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 511.130.01073 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 511.130.01030 Boehringer Ingelheim Investigational Site | Encinitas | California | — | — |
| 511.130.01028 Boehringer Ingelheim Investigational Site | Fair Oaks | California | — | — |
| 511.130.01037 Boehringer Ingelheim Investigational Site | Irvine | California | — | — |
| 511.130.01022 Boehringer Ingelheim Investigational Site | Sacramento | California | — | — |
| 511.130.01035 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 511.130.01052 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 511.130.01016 Boehringer Ingelheim Investigational Site | Torrance | California | — | — |
| 511.130.01021 Boehringer Ingelheim Investigational Site | Vista | California | — | — |
| 511.130.01051 Boehringer Ingelheim Investigational Site | Westlake Village | California | — | — |
| 511.130.01071 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 511.130.01053 Boehringer Ingelheim Investigational Site | Farmington | Connecticut | — | — |
| 511.130.01015 Boehringer Ingelheim Investigational Site | Groton | Connecticut | — | — |
| 511.130.01041 Boehringer Ingelheim Investigational Site | New Britain | Connecticut | — | — |
| 511.130.01064 Boehringer Ingelheim Investigational Site | Newark | Delaware | — | — |
| 511.130.01062 Boehringer Ingelheim Investigational Site | Washington D.C. | District of Columbia | — | — |
| 511.130.01003 Boehringer Ingelheim Investigational Site | Boynton Beach | Florida | — | — |
| 511.130.01056 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 511.130.01065 Boehringer Ingelheim Investigational Site | Daytona Beach | Florida | — | — |
| 511.130.01020 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 511.130.01024 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 511.130.01070 Boehringer Ingelheim Investigational Site | New Port Richey | Florida | — | — |
| 511.130.01043 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 511.130.01019 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 511.130.01061 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 511.130.01066 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 511.130.01001 Boehringer Ingelheim Investigational Site | West Palm Beach | Florida | — | — |
| 511.130.01002 Boehringer Ingelheim Investigational Site | West Palm Beach | Florida | — | — |
| 511.130.01009 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 511.130.01023 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 511.130.01008 Boehringer Ingelheim Investigational Site | Sandy Springs | Georgia | — | — |
| 511.130.01044 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 511.130.01034 Boehringer Ingelheim Investigational Site | Indianapolis | Indiana | — | — |
| 511.130.01067 Boehringer Ingelheim Investigational Site | Lafayette | Louisiana | — | — |
| 511.130.01013 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 511.130.01031 Boehringer Ingelheim Investigational Site | Bingham Farms | Michigan | — | — |
| 511.130.01006 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 511.130.01014 Boehringer Ingelheim Investigational Site | Billings | Montana | — | — |
| 511.130.01060 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 511.130.01057 Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | — | — |
| 511.130.01039 Boehringer Ingelheim Investigational Site | Moorestown | New Jersey | — | — |
| 511.130.01017 Boehringer Ingelheim Investigational Site | Endwell | New York | — | — |
| 511.130.01047 Boehringer Ingelheim Investigational Site | New Bern | North Carolina | — | — |
| 511.130.01027 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 511.130.01033 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 511.130.01004 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 511.130.01050 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 511.130.01059 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 511.130.01058 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 511.130.01012 Boehringer Ingelheim Investigational Site | Mayfield Heights | Ohio | — | — |
| 511.130.01072 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 511.130.01007 Boehringer Ingelheim Investigational Site | Eugene | Oregon | — | — |
| 511.130.01055 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 511.130.01048 Boehringer Ingelheim Investigational Site | Columbia | South Carolina | — | — |
| 511.130.01068 Boehringer Ingelheim Investigational Site | Mt. Pleasant | South Carolina | — | — |
| 511.130.01063 Boehringer Ingelheim Investigational Site | Knoxville | Tennessee | — | — |
| 511.130.01010 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 511.130.01036 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 511.130.01018 Boehringer Ingelheim Investigational Site | Corpus Christi | Texas | — | — |
| 511.130.01032 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 511.130.01011 Boehringer Ingelheim Investigational Site | Katy | Texas | — | — |
| 511.130.01026 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 511.130.01005 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 511.130.01069 Boehringer Ingelheim Investigational Site | Sandy City | Utah | — | — |
| 511.130.01040 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
| 511.130.01049 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
| 511.130.01029 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 511.130.01075 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 511.130.01054 Boehringer Ingelheim Investigational Site | Renton | Washington | — | — |
| 511.130.01045 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 511.130.01038 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00996372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2014 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00996372 live on ClinicalTrials.gov.